StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report report published on Friday morning. The firm issued a sell rating on the stock.
Separately, Cantor Fitzgerald reiterated an overweight rating and set a $2.50 price target on shares of VolitionRx in a report on Thursday, May 16th.
Check Out Our Latest Stock Report on VolitionRx
VolitionRx Price Performance
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Articles
- Five stocks we like better than VolitionRx
- Investing in Commodities: What Are They? How to Invest in Them
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What Are Dividends? Buy the Best Dividend Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How is Compound Interest Calculated?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.